Aquestive Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AQST | 42C.SI | AMPH | COLL | CPH.TO | HLS.TO | |
|---|---|---|---|---|---|---|
| Market cap | 476.94M | 515.12M | 1.19B | 770.59M | 331.16M | 131.47M |
| P/E (TTM) | — | — | 16.6 | 18.6 | 8.5 | — |
| Forward P/E | -6.7 | 247.4 | 8.8 | 3.3 | — | -43.2 |
| Price/book | -6.7 | 33.6 | 1.6 | 2.5 | 1.7 | 1.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.01% | +259.26% | +15.64% | −33.81% | −12.08% | −21.44% |
| Today | −2.06% | −3.09% | +3.32% | −0.25% | −0.31% | +0.47% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All AQST news ›Aquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call Transcript
Aquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call November 4, 2026 8:00 AM EST Faith Pomeroy-WardDaniel Barber - CEO, President & DirectorErnie Toth - Senior VP & CFOSherry Korczynski - Chief Commercial OfficerMelina Cioffi -…
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced financial results…
Aquestive Therapeutics GAAP EPS of -$0.18 misses by $0.06, revenue of $7.5M misses by $3.52M
Aquestive Therapeutics Q3 earnings missed on EPS and revenue as losses widened. - Aquestive Therapeutics press release (AQST): Q3 GAAP EPS of -$0.18 misses by $0.06. - Revenue of $7.5M (-41.5% Y/Y) misses by $3.52M.
Aquestive Therapeutics (AQST) Projected to Release Quarterly Earnings on Tuesday
Posted by Tristan Rich on Nov 2nd, 2026 Shares of AQST opened at $3.89 on Monday. The business’s 50 day moving average is $4.66 and its 200 day moving average is $4.20. The company has a market capitalization of $488.24 million, a PE ratio…
Single-dose oral challenge safely clears drug allergy labels in outpatients
Researchers report that 97 percent of patients given a direct oral drug challenge experienced no reaction at all, and the few reactions that did occur were mild. Among the whole cohort, 295 patients, or 97.0 percent, had no reaction during…
Epilepsy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharma, SK Biopharma
Epilepsy Pipeline 2026: FDA Updates, Therapy Innovations, openPR.com Epilepsy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia),…
Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock
Daniel Barber also recently made the following trade(s): NASDAQ:AQST opened at $3.78 on Monday. The stock’s fifty day moving average is $4.74 and its two-hundred day moving average is $4.35. Aquestive Therapeutics, Inc. has a 52 week low…
Aquestive Therapeutics moves R&D to HELIX in New Brunswick
Explore the BridgeTower Media network. 35 publications across 4 industries. Aquestive Therapeutics moves R&D to HELIX in New Brunswick H1 at HELIX in New Brunswick. - JESSICA PERRY/NJBIZ The HELIX in downtown New Brunswick is maintaining…
More from 1 other outlet
Aquestive Therapeutics: Bass reports about 7.5% stake
Aquestive Therapeutics (AQST) is a pharmaceutical company developing orally delivered and film-based medicines, including late-stage epinephrine prodrug candidates. - [SCHEDULE 13G] Aquestive Therapeutics, Inc. Passive Investment…
Stock Traders Buy Large Volume of Aquestive Therapeutics Put Options (NASDAQ:AQST)
Posted by Kim Johansen on Oct 16th, 2026 Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) saw unusually large options trading on Friday. Stock traders acquired 11,658 put options on the stock. This represents an increase of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- stocktitan.net2
- themarketsdaily.com2
- defenseworld.net1
- investingnews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.